Rao L. Divi, Ph.D.
Program Director, Methods and Technologies Branch
National Institutes of Health
National Cancer Institute
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
9609 Medical Center Drive, Rm. 4E118, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
telephone: (240) 276-6913
Carcinogenesis, transcriptomics, functional genomics, molecular markers, methods for risk assessment, toxicity and carcinogenicity, and high-throughput screening.
Ph.D. - Biochemistry
M.Sc. - Biochemistry
B.Sc. - Organic Chemistry
Dr. Divi is a Program Director in the Methods and Technologies Branch (MTB). His responsibilities include managing a research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and application and validation of emerging technologies developed in other research endeavors for cancer risk assessment. He is also the EGRP representative to the International Consortium on Lymphoma Epidemiologic Studies (InterLymph) and the International Multiple Myeloma Consortium (IMMC) and is a member of the Coordinating Committees for both consortia. Dr. Divi is a member of the Federation of American Societies for Experimental Biology (FASEB) "Breakthroughs in Bioscience" committee, which publishes articles to educate the general public about recent developments in basic biomedical research, the benefits of fundamental research, and how these research advances affect society.
He joined EGRP in 2008 from NCI's intramural Laboratory of Cancer Biology and Genetics. Since 1997, he had been a member of the Laboratory's Carcinogen-DNA Interactions Section, where he focused on understanding the genotoxicity of cisplatin, tamoxifen, PHIP, and benzo(a)pyrene, as well as the mitochondrial toxicity of antiretroviral drugs. A significant portion of Dr. Divi's work focused on identification of molecular biomarkers, development of methods, and validation of those markers through intra- and interlaboratory collaborations. He used these biomarkers in collaborative studies that assessed risk in humans and animal models.
Prior to joining NCI, Dr. Divi worked for four years at the National Center for Toxicological Research, which is the research arm of the U.S. Food and Drug Administration (FDA), in Jefferson, AR. Here he conducted research on the antithyroid activity of drugs and environmental toxicants. He also worked for a year on an International Atomic Energy Agency project on health effects of trace elements.